| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
48,181 |
42,177 |
$2.07M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
16,517 |
14,601 |
$555K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
3,798 |
3,369 |
$230K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
1,262 |
1,174 |
$181K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
3,907 |
3,465 |
$176K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
1,545 |
1,372 |
$117K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,821 |
3,060 |
$112K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
656 |
589 |
$54K |
| 62323 |
|
217 |
201 |
$29K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
2,818 |
2,371 |
$13K |
| 99490 |
Ccm add 20min |
925 |
895 |
$9K |
| 1036F |
|
4,269 |
3,721 |
$6K |
| 3288F |
|
3,505 |
3,121 |
$5K |
| 1101F |
|
2,971 |
2,648 |
$4K |
| 99457 |
|
260 |
218 |
$3K |
| 99454 |
|
182 |
145 |
$2K |
| J3490 |
Unclassified drugs |
374 |
311 |
$2K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
25 |
16 |
$1K |
| 99458 |
|
121 |
93 |
$952.57 |
| 96103 |
|
50 |
44 |
$530.37 |
| 77003 |
|
164 |
156 |
$358.66 |
| 99406 |
|
74 |
58 |
$215.44 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
7,659 |
6,224 |
$180.35 |
| Q9965 |
Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml |
289 |
253 |
$103.38 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
237 |
219 |
$94.43 |
| 96146 |
|
47 |
46 |
$62.22 |
| 1100F |
|
84 |
69 |
$50.00 |
| 0518F |
|
85 |
70 |
$50.00 |
| 99439 |
|
17 |
15 |
$30.59 |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
19 |
12 |
$24.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
7,421 |
6,470 |
$0.00 |
| G2196 |
Patient identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method |
148 |
120 |
$0.00 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
5,516 |
4,410 |
$0.00 |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
7,352 |
6,047 |
$0.00 |
| G8539 |
Functional outcome assessment documented as positive using a standardized tool and a care plan based on identified deficiencies is documented within two days of the functional outcome assessment |
129 |
102 |
$0.00 |
| G2200 |
Patient identified as an unhealthy alcohol user received brief counseling |
148 |
120 |
$0.00 |
| G9622 |
Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method |
6,954 |
6,167 |
$0.00 |
| G9621 |
Patient identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method and received brief counseling |
727 |
622 |
$0.00 |
| G9991 |
Patient received any pneumococcal conjugate or polysaccharide vaccine on or after their 19th birthday and before the end of the measurement period |
45 |
33 |
$0.00 |
| G8483 |
Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) |
48 |
46 |
$0.00 |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
4,208 |
3,738 |
$0.00 |
| G8950 |
Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented |
10,856 |
9,538 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
4,743 |
4,087 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
4,340 |
3,855 |
$0.00 |
| G8734 |
Elder maltreatment screen documented as negative, follow-up is not required |
1,005 |
843 |
$0.00 |
| M1207 |
Patient is screened for food insecurity, housing instability, transportation needs, utility difficulties, and interpersonal safety |
2,864 |
2,527 |
$0.00 |
| G2197 |
Patient screened for unhealthy alcohol use using a systematic screening method and not identified as an unhealthy alcohol user |
2,832 |
2,539 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
1,836 |
1,637 |
$0.00 |
| 1123F |
|
94 |
80 |
$0.00 |
| G8418 |
Bmi is documented below normal parameters and a follow-up plan is documented |
18 |
15 |
$0.00 |